🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Britain launches coronavirus vaccine taskforce

Published 17/04/2020, 17:18
SASY
-

LONDON (Reuters) - Britain launched a new coronavirus taskforce on Friday to support efforts to make a vaccine available to the public as quickly as possible.

The government said 21 new research projects would get funding from a 14 million pound investment pool "to rapidly progress treatments and vaccines".

The taskforce will include AstraZeneca and research charity the Wellcome Trust.

A million doses of a potential COVID-19 vaccine being developed by British scientists at Oxford University are already being manufactured, even before trials prove whether the shot is effective, the team said on Friday.

"UK scientists are working as fast as they can to find a vaccine that fights coronavirus, saving and protecting people’s lives. We stand firmly behind them in their efforts," business minister Alok Sharma said.

"The Vaccine Taskforce is key to coordinating efforts to rapidly accelerate the development and manufacture of a potential new vaccine, so we can make sure it is widely available to patients as soon as possible."

A vaccine against the novel coronavirus is seen as key to defeating the COVID-19 pandemic which has killed over 100,000 globally and delivered a large blow to the global economy.

But timeframes for its development vary.

While the Oxford scientists said their vaccine would be available by September, GlaxoSmithKline Plc and Sanofi (PA:SASY) SA, who earlier this week said they would develop a vaccine, forecast that it would not be available until the second half of 2021.

Britain's government said it wanted a vaccine to be available as quickly as possible but did not give more details on an expected timetable for development.

The taskforce will be led by Chief Scientific Adviser Patrick Vallance and Deputy Chief Medical Officer Professor Jonathan van Tam, and will aim to make sure regulations and manufacturing capacity are such that the production of a vaccine can be quickly scaled up when one is successfully developed.

Britain said it would identify ways to fast-track clinical trials and also continue to support international efforts to find a vaccine.

Among the projects to receive funding include a test of a vaccine at Imperial College, London that aims for the body to produce more protective antibodies; Public Health England's efforts to develop a new antibody to protect from COVID-19 and a University of Oxford trial of an anti-malarial drug to see if it could prove effective against COVID-19.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.